?:authorAffiliation
|
-
[\'Christopher D. Barrett, Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, and the Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Divisions of Acute Care Surgery, Trauma and Surgical Critical Care and Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Dr. Barrett has patents pending related to the field of fibrinolysis and COVID-19 therapy. Email: cdbarret@mit.edu.\', \'Michael B. Yaffe, Chief Scientific Advisor and Academic Editor, Science Signaling, American Association for the Advancement of Science, Washington, DC 20005, USA. Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, and the Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Divisions of Acute Care Surgery, Trauma and Surgical Critical Care and Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Dr. Yaffe has patents pending related to the field of fibrinolysis and COVID-19 therapy. Email: myaffe@mit.edu.\']
|